Latest Articles

In laboratory tests, bioactive glasses doped with gallium oxide killed more than 99% of osteosarcoma cells, while leaving healthy human osteoblasts unharmed. This could one day form the basis of new bone cancer treatments, researchers say.

Researchers investigated the ability of metformin to protect human cells and mice from DNA damage due to radiation exposure. If successfully repurposed, the drug has the potential to help at-risk groups, such as cancer patients and astronauts.

We spoke to physician–scientist Professor Pradipta Ghosh about what drove her to follow this career path, her current work, the value of and challenges faced by physician–scientists and advice for those who are considering following in her footsteps.

Dr. David Bending discusses his research interests and experience as an LGBTQIA+ immunologist. He offers advice for others beginning a career in STEMM and highlights the importance of LGBTQIA+ representation.

In this interview, we spoke to Dr. Raquel Cuella Martin to learn about her research, her experiences working as an LGBTQIA+ researcher in STEMM and her advice for others beginning a STEMM career.

In this interview, Jay Mandula describes his work in immuno-oncology, the challenges of being transgender in Florida and how increased visibility of LGBTQIA+ scientists can impact STEMM.

Dr. Stephen Robinson reflects on his career, LGBTQIA+ identity and mentorship. He emphasizes the importance of authenticity, visibility, and supporting the next generation of scientists in their unique paths.

In this interview, Avery Cunningham discusses the creation of STEM, LGBTQ & You, his experiences as a queer person in STEMM and the barriers that face LGBTQ+ individuals in the field.

In this interview, Alex Freeman, the founder of Octopus, discusses the progress made since the platform's launch and the ongoing challenges of establishing a new paradigm in academic publishing.

Scientists have taken a fresh approach to finding a way to target neuroblastoma, the most common solid tumor of infancy. Their novel gene target could offer hope for finding alternative treatments with fewer long-term side effects.